Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Bo Lagerqvist, M.D., Ph.D., Stefan K. James, M.D., Ph.D., Ulf Stenestrand, M.D., Ph.D., Johan Lindbäck, M.Sc., Tage Nilsson, M.D., Ph.D., Lars Wallentin, M.D., Ph.D., for the SCAAR Study Group
Background Recent reports have indicated that there may be anincreased risk of late stent thrombosis with the use of drug-elutingstents, as compared with bare-metal stents.
Methods We evaluated 6033 patients treated with drug-elutingstents and 13,738 patients treated with bare-metal stents in2003 and 2004, using data from the Swedish Coronary Angiographyand Angioplasty Registry. The outcome analysis covering a periodof up to 3 years was based on 1424 deaths and 2463 myocardialinfarctions and was adjusted for differences in baseline characteristics.
Results The two study groups did not differ significantly inthe composite of death and myocardial infarction during 3 yearsof follow-up. At 6 months, there was a trend toward a lowerunadjusted event rate in patients with drug-eluting stents thanin those with bare-metal stents, with 13.4 fewer such eventsper 1000 patients. However, after 6 months, patients with drug-elutingstents had a significantly higher event rate, with 12.7 moreevents per 1000 patients per year (adjusted relative risk, 1.20;95% confidence interval [CI], 1.05 to 1.37). At 3 years, mortalitywas significantly higher in patients with drug-eluting stents(adjusted relative risk, 1.18; 95% CI, 1.04 to 1.35), and from6 months to 3 years, the adjusted relative risk for death inthis group was 1.32 (95% CI, 1.11 to 1.57).
Conclusions Drug-eluting stents were associated with an increasedrate of death, as compared with bare-metal stents. This trendappeared after 6 months, when the risk of death was 0.5 percentagepoint higher and a composite of death or myocardial infarctionwas 0.5 to 1.0 percentage point higher per year. The long-termsafety of drug-eluting stents needs to be ascertained in large,randomized trials.
Source Information
From the Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala (B.L., S.K.J., J.L., T.N., L.W.); and Linköping University Hospital, Linköping (U.S.) — both in Sweden. This article (10.1056/NEJMoa067722) was published at www.nejm.org on February 12, 2007.
Address reprint requests to Dr. Lagerqvist at the Uppsala Clinical Research Center, Uppsala University Hospital, 751 85 Uppsala, Sweden, or at bo.lagerqvist{at}ucr.uu.se.
American College of Cardiology Foundation, , American Heart Association Task Force on Practice, , American Society of Echocardiography, , American Society of Nuclear Cardiology, , Heart Rhythm Society, , Society of Cardiovascular Anesthesiologists, , Society for Cardiovascular Angiography and Interve, , Society for Vascular Medicine, , Society for Vascular Surgery, , Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F.
(2009). 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. J Am Coll Cardiol
54: e13-e118
[Full Text]
2007 WRITING COMMITTEE MEMBERS, , Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F.
(2009). 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation
120: e169-e276
[Full Text]
Carter, A. J.
(2009). Drug-eluting stent fracture promise and performance.. J Am Coll Cardiol
54: 1932-1934
[Full Text]
Stenestrand, U., James, S. K., Lindback, J., Frobert, O., Carlsson, J., Schersten, F., Nilsson, T., Lagerqvist, B., for the SCAAR/SWEDEHEART study group,
(2009). Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J
0: ehp424v1-ehp424
[Abstract][Full Text]
Kenney, K. M., Marzo, M. C., Ondrasik, N. R., Wisenbaugh, T.
(2009). Percutaneous Coronary Intervention Outcomes in a Low-Volume Center: Survival, Stent Thrombosis, and Repeat Revascularization. Circ Cardiovasc Qual Outcomes
2: 671-677
[Abstract][Full Text]
George, J. C., Dangas, G. D.
(2009). European Society of Cardiology Congress 2009: Update in Interventional Cardiology. J Am Coll Cardiol Intv
2: 1160-1162
[Full Text]
Harjai, K J, Shenoy, C, Orshaw, P, Boura, J
(2009). Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart
95: 1579-1586
[Abstract][Full Text]
Di Lorenzo, E., Sauro, R., Varricchio, A., Carbone, G., Cortese, G., Capasso, M., Lanzillo, T., Manganelli, F., Mariello, C., Siano, F., Pagliuca, M. R., Stanco, G., Rosato, G., De Luca, G.
(2009). Long-Term Outcome of Drug-Eluting Stents Compared With Bare Metal Stents in ST-Segment Elevation Myocardial Infarction: Results of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation
120: 964-972
[Abstract][Full Text]
Cannon, C. P.
(2009). Should We Manage Patients With Non-ST Segment Elevation Myocardial Infarction With Renal Failure With an Invasive Strategy?. Circulation
120: 828-830
[Full Text]
Caixeta, A., Leon, M. B., Lansky, A. J., Nikolsky, E., Aoki, J., Moses, J. W., Schofer, J., Morice, M.-C., Schampaert, E., Kirtane, A. J., Popma, J. J., Parise, H., Fahy, M., Mehran, R.
(2009). 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.. J Am Coll Cardiol
54: 894-902
[Abstract][Full Text]
Menozzi, A., Solinas, E., Ortolani, P., Repetto, A., Saia, F., Piovaccari, G., Manari, A., Magagnini, E., Vignali, L., Bonizzoni, E., Merlini, P. A., Cavallini, C., Ardissino, D., for the SES-SMART Investigators,
(2009). Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J
30: 2095-2101
[Abstract][Full Text]
Swedberg, K.
(2009). Fallacies in clinical cardiovascular trials. Heart
95: 1464-1468
[Full Text]
Lee, J. Y., Park, D.-W., Yun, S.-C., Lee, S.-W., Kim, Y.-H., Lee, C. W., Hong, M.-K., Park, S.-W., Park, S.-J.
(2009). Long-Term Clinical Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents for Patients With Unprotected Left Main Coronary Artery Disease Analysis of the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) Registry.. J Am Coll Cardiol
54: 853-859
[Abstract][Full Text]
O'Neill, W. W.
(2009). A Case Against Low-Volume Percutaneous Coronary Intervention Centers. Circulation
120: 546-548
[Full Text]
Kim, Y.-H., Park, D.-W., Lee, S.-W., Yun, S.-C., Lee, C. W., Hong, M.-K., Park, S.-W., Seung, K. B., Gwon, H.-C., Jeong, M.-H., Jang, Y., Kim, H.-S., Seong, I.-W., Park, H. S., Ahn, T., Chae, I.-H., Tahk, S.-J., Chung, W.-S., Park, S.-J., for the Revascularization for Unprotected Left Mai,
(2009). Long-Term Safety and Effectiveness of Unprotected Left Main Coronary Stenting With Drug-Eluting Stents Compared With Bare-Metal Stents. Circulation
120: 400-407
[Abstract][Full Text]
Vlaar, P. J., Zijlstra, F.
(2009). Angiographic Restenosis and Clinical Recurrence After Sirolimus- and Paclitaxel-Eluting Stent Implantation. J Am Coll Cardiol Intv
2: 776-778
[Full Text]
Unverdorben, M., Vallbracht, C., Cremers, B., Heuer, H., Hengstenberg, C., Maikowski, C., Werner, G. S., Antoni, D., Kleber, F. X., Bocksch, W., Leschke, M., Ackermann, H., Boxberger, M., Speck, U., Degenhardt, R., Scheller, B.
(2009). Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis. Circulation
119: 2986-2994
[Abstract][Full Text]
Leon, M. B., Allocco, D. J., Dawkins, K. D., Baim, D. S.
(2009). Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events. J Am Coll Cardiol Intv
2: 504-512
[Abstract][Full Text]
Di Lorenzo, E., De Luca, G., Sauro, R., Varricchio, A., Capasso, M., Lanzillo, T., Manganelli, F., Mariello, C., Siano, F., Pagliuca, M. R., Stanco, G., Rosato, G.
(2009). The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. J Am Coll Cardiol Intv
2: 515-523
[Abstract][Full Text]
Takagi, T., Okura, H., Kobayashi, Y., Kataoka, T., Taguchi, H., Toda, I., Tamita, K., Yamamuro, A., Sakanoue, Y., Ito, A., Yanagi, S., Shimeno, K., Waseda, K., Yamasaki, M., Fitzgerald, P. J., Ikeno, F., Honda, Y., Yoshiyama, M., Yoshikawa, J., for the POPPS Investigators,
(2009). A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). J Am Coll Cardiol Intv
2: 524-531
[Abstract][Full Text]
Ko, D. T., Chiu, M., Guo, H., Austin, P. C., Goeree, R., Cohen, E., Labinaz, M., Tu, J. V.
(2009). Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.. J Am Coll Cardiol
53: 1773-1782
[Abstract][Full Text]
James, S. K., Stenestrand, U., Lindback, J., Carlsson, J., Schersten, F., Nilsson, T., Wallentin, L., Lagerqvist, B., the SCAAR Study Group,
(2009). Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden. NEJM
360: 1933-1945
[Abstract][Full Text]
Brar, S. S., Leon, M. B., Stone, G. W., Mehran, R., Moses, J. W., Brar, S. K., Dangas, G.
(2009). Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.. J Am Coll Cardiol
53: 1677-1689
[Abstract][Full Text]
Douglas, P. S., Brennan, J. M., Anstrom, K. J., Sedrakyan, A., Eisenstein, E. L., Haque, G., Dai, D., Kong, D. F., Hammill, B., Curtis, L., Matchar, D., Brindis, R., Peterson, E. D.
(2009). Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol
53: 1629-1641
[Abstract][Full Text]
Awata, M., Nanto, S., Uematsu, M., Morozumi, T., Watanabe, T., Onishi, T., Iida, O., Sera, F., Minamiguchi, H., Kotani, J.-i., Nagata, S.
(2009). Heterogeneous Arterial Healing in Patients Following Paclitaxel-Eluting Stent Implantation: Comparison With Sirolimus-Eluting Stents. J Am Coll Cardiol Intv
2: 453-458
[Abstract][Full Text]
Weisz, G., Leon, M. B., Holmes, D. R. Jr, Kereiakes, D. J., Popma, J. J., Teirstein, P. S., Cohen, S. A., Wang, H., Cutlip, D. E., Moses, J. W.
(2009). Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.. J Am Coll Cardiol
53: 1488-1497
[Abstract][Full Text]
Carlsson, J., James, S. K., Lindback, J., Schersten, F., Nilsson, T., Stenestrand, U., Lagerqvist, B., for the SCAAR (Swedish Coronary Angiography and An,
(2009). Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria. J Am Coll Cardiol
53: 1389-1398
[Abstract][Full Text]
Li, Y., Zheng, Z., Xu, B., Zhang, S., Li, W., Gao, R., Hu, S.
(2009). Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution. Circulation
119: 2040-2050
[Abstract][Full Text]
Calvert, P. A., Bennett, M. R.
(2009). Restenosis Revisited. Circ. Res.
104: 823-825
[Full Text]
Byrne, R. A., Mehilli, J., Iijima, R., Schulz, S., Pache, J., Seyfarth, M., Schomig, A., Kastrati, A., for the Intracoronary Stenting and Angiographic Re,
(2009). A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J
30: 923-931
[Abstract][Full Text]
Horst, B., Rihal, C. S., Holmes, D. R. Jr, Bresnahan, J. F., Prasad, A., Gau, G., Lennon, R., Lerman, A.
(2009). Comparison of Drug-Eluting and Bare-Metal Stents for Stable Coronary Artery Disease. J Am Coll Cardiol Intv
2: 321-328
[Abstract][Full Text]
Shishehbor, M. H., Filby, S. J., Chhatriwalla, A. K., Christofferson, R. D., Jain, A., Kapadia, S. R., Lincoff, A. M., Bhatt, D. L., Ellis, S. G.
(2009). Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia. J Am Coll Cardiol Intv
2: 329-336
[Abstract][Full Text]
Samady, H., McDaniel, M., Veledar, E., De Bruyne, B., Pijls, N. H., Fearon, W. F., Vaccarino, V.
(2009). Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment. J Am Coll Cardiol Intv
2: 357-363
[Abstract][Full Text]
Eisenberg, M. J., Richard, P. R., Libersan, D., Filion, K. B.
(2009). Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents. Circulation
119: 1634-1642
[Abstract][Full Text]
Kaul, U, Bhatia, V
(2009). Choice of DES: is there a difference?. Heart Asia
2009: 11-15
[Abstract][Full Text]
Applegate, R. J., Sacrinty, M. T., Kutcher, M. A., Santos, R. M., Gandhi, S. K., Little, W. C.
(2009). 3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents. J Am Coll Cardiol Intv
2: 231-239
[Abstract][Full Text]
Kaltoft, A., Jensen, L. O., Maeng, M., Tilsted, H. H., Thayssen, P., Bottcher, M., Lassen, J. F., Krusell, L. R., Rasmussen, K., Hansen, K. N., Pedersen, L., Johnsen, S. P., Sorensen, H. T., Thuesen, L.
(2009). 2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents Results From the WDHR (Western Denmark Heart Registry).. J Am Coll Cardiol
53: 658-664
[Abstract][Full Text]
Stefanadis, C., Toutouzas, K.
(2009). Paclitaxel versus sirolimus the battle is still ongoing.. J Am Coll Cardiol
53: 665-666
[Full Text]
Ryan, J., Linde-Zwirble, W., Engelhart, L., Cooper, L., Cohen, D. J.
(2009). Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program. Circulation
119: 952-961
[Abstract][Full Text]
Kimura, T., Morimoto, T., Nakagawa, Y., Tamura, T., Kadota, K., Yasumoto, H., Nishikawa, H., Hiasa, Y., Muramatsu, T., Meguro, T., Inoue, N., Honda, H., Hayashi, Y., Miyazaki, S., Oshima, S., Honda, T., Shiode, N., Namura, M., Sone, T., Nobuyoshi, M., Kita, T., Mitsudo, K., for the j-Cypher Registry Investigators,
(2009). Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation. Circulation
119: 987-995
[Abstract][Full Text]
Stahli, B. E., Camici, G. G., Tanner, F. C.
(2009). Drug-eluting stent thrombosis. Ther Adv Cardiovasc Dis
3: 45-52
[Abstract]
Park, S.-J., Park, D.-W.
(2009). Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Is It Time to Change Guidelines?. Circ Cardiovasc Interv
2: 59-68
[Abstract][Full Text]
Lim, H. S., Farouque, O., Andrianopoulos, N., Yan, B. P., Lim, C. C.S., Brennan, A. L., Reid, C. M., Freeman, M., Charter, K., Black, A., New, G., Ajani, A. E., Duffy, S. J., Clark, D. J., on behalf of the Melbourne Interventional Group,
(2009). Survival of Elderly Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction Complicated by Cardiogenic Shock. J Am Coll Cardiol Intv
2: 146-152
[Abstract][Full Text]
Philpott, A. C. MD, Southern, D. A. MSc, Clement, F. M. PhD, Galbraith, P. D. BN MSc, Traboulsi, M. MD, Knudtson, M. L. MD, Ghali, W. A. MD, for the APPROACH Investigators,
(2009). Long-term outcomes of patients receiving drug-eluting stents. CMAJ
180: 167-174
[Abstract][Full Text]
Genereux, P. MD, Mehran, R. MD
(2009). Are drug-eluting stents safe in the long term?. CMAJ
180: 154-155
[Full Text]
Authors/writing members:, , Daemen, J., Simoons, M. L., Wijns, W., Bagust, A., Bos, G., Bowen, J. M., Braunwald, E., Camenzind, E., Chevalier, B., DiMario, C., Fajadet, J., Gitt, A., Guagliumi, G., Hillege, H. L., James, S., Juni, P., Kastrati, A., Kloth, S., Kristensen, S. D., Krucoff, M., Legrand, V., Pfisterer, M., Rothman, M., Serruys, P. W., Silber, S., Steg, P. G., Tariah, I., Wallentin, L., Windecker, S. W., Participants in the Forum:, , Aimonetti, A., Allocco, D., Baczynska, A., Bagust, A., Berenger, M., Bos, G., Boam, A., Bowen, J.M., Braunwald, E., Calle, J.P., Camenzind, E., Campo, G., Carlier, S., Chevalier, B., Daemen, J., de Schepper, J., Di Bisceglie, G., DiMario, C., Dobbels, H., Fajadet, J., Farb, A., Ghislain, J.C., Gitt, A., Guagliumi, G., Hellbardt, S., Hillege, H.L., ten Hoedt, R., Isaia, C., James, S., de Jong, P., Juni, P., Kastrati, A., Klasen, E., Kloth, S., Kristensen, S.D., Krucoff, M., Legrand, V., Lekehal, M., LeNarz, L., Ni Mhullain, F., Nagai, H., Patteet, A., Paunovic, D., Pfisterer, M., Potgieter, A., Purdy, I., Raveau-Landon, C., Rothman, M., Serruys, P.W., Silber, S., Simoons, M.L., Steg, P.G., Tariah, I., Ternstrom, S., Van Wuytswinkel, J., Waliszewski, M., Wallentin, L., Wijns, W., Windecker, S.W.
(2009). Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. Eur Heart J
30: 152-161
[Full Text]
Terpening, C.
(2009). An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. J Am Board Fam Med
22: 51-56
[Abstract][Full Text]
Pfisterer, M., Brunner-La Rocca, H. P., Rickenbacher, P., Hunziker, P., Mueller, C., Nietlispach, F., Leibundgut, G., Bader, F., Kaiser, C., for the BASKET Investigators,
(2009). Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J
30: 16-24
[Abstract][Full Text]
Park, S.-J., Kim, Y.-H.
(2008). Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia. Circulation
118: 2730-2737
[Full Text]
Burzotta, F., Parma, A., Pristipino, C., Manzoli, A., Belloni, F., Sardella, G., Rigattieri, S., Danesi, A., Mazzarotto, P., Summaria, F., Romagnoli, E., Prati, F., Trani, C., Crea, F.
(2008). Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J
29: 3011-3021
[Abstract][Full Text]
Shemin, R. J.
(2008). Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof?. Circulation
118: 2326-2329
[Full Text]
Ostovan, M. A, Mollazadeh, R., Kojuri, J., Mirabadi, M.
(2008). Experience with Paclitaxel-Eluting Infinnium Coronary Stents. Asian Cardiovasc. Thorac. Ann.
16: 454-458
[Abstract][Full Text]
Jensen, L. O., Maeng, M., Thayssen, P., Kaltoft, A., Tilsted, H. H., Bottcher, M., Lassen, J. F., Hansen, K. N., Krusell, L. R., Rasmussen, K., Pedersen, K. E., Pedersen, L., Paaske Johnsen, S., Sorensen, H. T., Thuesen, L.
(2008). Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Circ Cardiovasc Interv
1: 176-184
[Abstract][Full Text]
Hamilos, M., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Beleslin, B., Sagic, D., De Bruyne, B., Bartunek, J., Wijns, W.
(2008). Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses. Circ Cardiovasc Interv
1: 193-200
[Abstract][Full Text]
Colombo, A., Gerber, R. T.
(2008). Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely. Circ Cardiovasc Interv
1: 226-232
[Full Text]
Pfisterer, M. E
(2008). Commentary on drug-eluting stents: to use or not to use--that is the question!. Heart
94: 1648-1650
[Full Text]
Alfonso, F., Perez-Vizcayno, M.-J., Hernandez, R., Bethencourt, A., Marti, V., Lopez-Minguez, J. R., Angel, J., Iniguez, A., Moris, C., Cequier, A., Sabate, M., Escaned, J., Jimenez-Quevedo, P., Banuelos, C., Suarez, A., Macaya, C., for the RIBS-II Investigators,
(2008). Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study. J Am Coll Cardiol
52: 1621-1627
[Abstract][Full Text]
Go, A. S., Magid, D. J., Wells, B., Sung, S. H., Cassidy-Bushrow, A. E., Greenlee, R. T., Langer, R. D., Lieu, T. A., Margolis, K. L., Masoudi, F. A., McNeal, C. J., Murata, G. H., Newton, K. M., Novotny, R., Reynolds, K., Roblin, D. W., Smith, D. H., Vupputuri, S., White, R. E., Olson, J., Rumsfeld, J. S., Gurwitz, J. H.
(2008). The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research. Circ Cardiovasc Qual Outcomes
1: 138-147
[Abstract][Full Text]
Byrne, R. A., Kastrati, A.
(2008). Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. Eur Heart J Suppl
10: I25-I29
[Abstract][Full Text]
Mauri, L., Silbaugh, T. S., Wolf, R. E., Zelevinsky, K., Lovett, A., Zhou, Z., Resnic, F. S., Normand, S.-L. T.
(2008). Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts. Circulation
118: 1817-1827
[Abstract][Full Text]
King, S. B. III, Hannan, E. L.
(2008). Mounting Evidence for Safety and Improved Outcomes of Drug-Eluting Stenting: But Is It the Stent?. Circulation
118: 1783-1784
[Full Text]
Lin, G. A., Dudley, R. A., Lucas, F. L., Malenka, D. J., Vittinghoff, E., Redberg, R. F.
(2008). Frequency of Stress Testing to Document Ischemia Prior to Elective Percutaneous Coronary Intervention. JAMA
300: 1765-1773
[Abstract][Full Text]
Park, D.-W., Yun, S.-C., Lee, S.-W., Kim, Y.-H., Lee, C. W., Hong, M.-K., Cheong, S.-S., Kim, J.-J., Park, S.-W., Park, S.-J.
(2008). Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents. J Am Coll Cardiol Intv
1: 494-503
[Abstract][Full Text]
Costa, J. R. Jr, Abizaid, A., Costa, R., Feres, F., Tanajura, L. F., Abizaid, A., Mattos, L. A., Staico, R., Siqueira, D., Sousa, A. G.M.R., Bonan, R., Sousa, J. E.
(2008). Preliminary Results of the Hydroxyapatite Nonpolymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting Stent System. J Am Coll Cardiol Intv
1: 545-551
[Abstract][Full Text]
Wenaweser, P., Daemen, J., Zwahlen, M., van Domburg, R., Juni, P., Vaina, S., Hellige, G., Tsuchida, K., Morger, C., Boersma, E., Kukreja, N., Meier, B., Serruys, P. W., Windecker, S.
(2008). Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study. J Am Coll Cardiol
52: 1134-1140
[Abstract][Full Text]
Shishehbor, M. H., Goel, S. S., Kapadia, S. R., Bhatt, D. L., Kelly, P., Raymond, R. E., Galla, J. M., Brener, S. J., Whitlow, P. L., Ellis, S. G.
(2008). Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. J Am Coll Cardiol
52: 1041-1048
[Abstract][Full Text]
Nallamothu, B. K., Hayward, R. A., Bates, E. R.
(2008). Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation
118: 1294-1303
[Full Text]
Nakazawa, G., Finn, A. V., Joner, M., Ladich, E., Kutys, R., Mont, E. K., Gold, H. K., Burke, A. P., Kolodgie, F. D., Virmani, R.
(2008). Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study. Circulation
118: 1138-1145
[Abstract][Full Text]
Kiaii, B., McClure, R. S., Stewart, P., Rayman, R., Swinamer, S. A., Suematsu, Y., Fox, S., Higgins, J., Albion, C., Kostuk, W. J., Almond, D., Sridhar, K., Teefy, P., Jablonsky, G., Diamantouros, P., Dobkowski, W. B., Jones, P., Bainbridge, D., Iglesias, I., Murkin, J., Cheng, D., Novick, R. J.
(2008). Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up. J. Thorac. Cardiovasc. Surg.
136: 702-708
[Abstract][Full Text]
Chieffo, A., Park, S.-J., Meliga, E., Sheiban, I., Lee, M. S., Latib, A., Kim, Y.-H., Valgimigli, M., Sillano, D., Magni, V., Biondi-Zoccai, G., Montorfano, M., Airoldi, F., Rogacka, R., Carlino, M., Michev, I., Lee, C.-W., Hong, M.-K., Park, S.-W., Moretti, C., Bonizzoni, E., Sangiorgi, G. M., Tobis, J., Serruys, P. W., Colombo, A.
(2008). Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J
29: 2108-2115
[Abstract][Full Text]
Anstrom, K. J., Kong, D. F., Shaw, L. K., Califf, R. M., Kramer, J. M., Peterson, E. D., Rao, S. V., Matchar, D. B., Mark, D. B., Harrington, R. A., Eisenstein, E. L.
(2008). Long-term Clinical Outcomes Following Coronary Stenting. Arch Intern Med
168: 1647-1655
[Abstract][Full Text]
Austin, D., Oldroyd, K. G., McConnachie, A., Slack, R., Eteiba, H., Flapan, A. D., Jennings, K. P., Northcote, R. J., Pell, A. C.H., Starkey, I. R., Pell, J. P.
(2008). Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study. Circ Cardiovasc Interv
1: 45-52
[Abstract][Full Text]
Brodie, B. R., Stuckey, T., Downey, W., Humphrey, A., Bradshaw, B., Metzger, C., Hermiller, J., Krainin, F., Juk, S., Cheek, B., Duffy, P., Smith, H., Edmunds, J., Varanasi, J., Simonton, C. A., STENT (Strategic Transcatheter Evaluation of New T,
(2008). Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Intv
1: 405-414
[Abstract][Full Text]
Holmes, D. R. Jr, Teirstein, P. S., Satler, L., Sketch, M. H. Jr, Popma, J. J., Mauri, L., Wang, H., Schleckser, P. A., Cohen, S. A., SISR Investigators,
(2008). 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial. J Am Coll Cardiol Intv
1: 439-448
[Abstract][Full Text]
Head, D. E., Barash, P.
(2008). Progress Is Precarious. Anesth. Analg.
107: 362-364
[Full Text]
Newsome, L. T., Kutcher, M. A., Royster, R. L.
(2008). Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesth. Analg.
107: 552-569
[Abstract][Full Text]
Bates, E. R., Nallamothu, B. K.
(2008). Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction. Circulation
118: 567-573
[Full Text]
Booth, J., Clayton, T., Pepper, J., Nugara, F., Flather, M., Sigwart, U., Stables, R. H., on Behalf of the SoS Investigators,
(2008). Randomized, Controlled Trial of Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: Six-Year Follow-Up From the Stent or Surgery Trial (SoS). Circulation
118: 381-388
[Abstract][Full Text]
Malenka, D. J., Kaplan, A. V., Lucas, F. L., Sharp, S. M., Skinner, J. S.
(2008). Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents. JAMA
299: 2868-2876
[Abstract][Full Text]
Alfonso, F.
(2008). The "vulnerable" stent why so dreadful?. J Am Coll Cardiol
51: 2403-2406
[Full Text]
Dixon, S. R., Grines, C. L., O'Neill, W. W.
(2008). The year in interventional cardiology.. J Am Coll Cardiol
51: 2355-2369
[Full Text]
Brar, S. S., Kim, J., Brar, S. K., Zadegan, R., Ree, M., Liu, I.-L. A., Mansukhani, P., Aharonian, V., Hyett, R., Shen, A. Y.-J.
(2008). Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.. J Am Coll Cardiol
51: 2220-2227
[Abstract][Full Text]
Choi, S.-H., Prasad, A., Tsimikas, S.
(2008). The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.. J Am Coll Cardiol
51: 2228-2229
[Full Text]
Hamilos, M. I., Ostojic, M., Beleslin, B., Sagic, D., Mangovski, L., Stojkovic, S., Nedeljkovic, M., Orlic, D., Milosavljevic, B., Topic, D., Karanovic, N., Wijns, W., on behalf of the NOBORI CORE Investigators,
(2008). Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.. J Am Coll Cardiol
51: 2123-2129
[Abstract][Full Text]
Muhlestein, J. B.
(2008). Endothelial dysfunction associated with drug-eluting stents what, where, when, and how?. J Am Coll Cardiol
51: 2139-2140
[Full Text]
Austin, D., Oldroyd, K. G., McConnachie, A., Slack, R., Eteiba, H., Flapan, A. D., Jennings, K. P., Northcote, R. J., Pell, A. C. H., Starkey, I. R., Pell, J. P.
(2008). Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. J Public Health (Oxf)
30: 186-193
[Abstract][Full Text]
Li, J., Jabara, R., Pendyala, L., Otsuka, Y., Shinke, T., Hou, D., Robinson, K., Chronos, N.
(2008). Abnormal Vasomotor Function of Porcine Coronary Arteries Distal to Sirolimus-Eluting Stents. J Am Coll Cardiol Intv
1: 279-285
[Abstract][Full Text]
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A.
(2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 776S-814S
[Abstract][Full Text]
Groeneveld, P. W., Matta, M. A., Greenhut, A. P., Yang, F.
(2008). Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients. J Am Coll Cardiol
51: 2017-2024
[Abstract][Full Text]